[go: up one dir, main page]

AR084865A1 - Preparacion de desintegracion rapida, comprimido dispersable por via oral - Google Patents

Preparacion de desintegracion rapida, comprimido dispersable por via oral

Info

Publication number
AR084865A1
AR084865A1 ARP120100142A ARP120100142A AR084865A1 AR 084865 A1 AR084865 A1 AR 084865A1 AR P120100142 A ARP120100142 A AR P120100142A AR P120100142 A ARP120100142 A AR P120100142A AR 084865 A1 AR084865 A1 AR 084865A1
Authority
AR
Argentina
Prior art keywords
preparation
drug
medicament
oral
granules
Prior art date
Application number
ARP120100142A
Other languages
English (en)
Inventor
Yutaka Tanoue
Tetsuya Matsuura
Yutaka Yamagata
Naoki Nagahara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084865(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR084865A1 publication Critical patent/AR084865A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Una preparación con una propiedad de desintegración mejorada, una preparación que muestra una biodisponibilidad mejorada de un medicamento, los métodos de producción de la misma y similares. Una preparación de desintegración rápida que comprende gránulos que comprenden el medicamento recubierto con una capa de recubrimiento que contiene azúcar o un alcohol de azúcar; y un desintegrante. Un método de producción de una preparación de desintegración rápida que incluye un paso de producción de gránulos que comprenden el medicamento, un paso de formación de una capa de recubrimiento que contiene azúcar o un alcohol de azúcar sobre los gránulos obtenidos y un paso de mezcla de los gránulos recubiertos con un desintegrante y el moldeo de la mezcla.Reivindicación 7: La preparación de acuerdo con la reivindicación 5 ó 6, caracterizado porque es un comprimido. Reivindicación 9: Una preparación para absorción oral-mucosa caracterizado porque comprende (S)-N-[2-(1,6,7,8-tetrahidro-2H-indeno[5,4-b]furan-8-il)etil]propionamida como un medicamento; que muestra una proporción más alta del medicamento en una forma no modificada y un metabolito del medicamento luego de la transferencia dentro de la sangre en lugar de la administración por vía oral. Reivindicación 24: Un fármaco para la profilaxis y/o tratamiento de un trastorno bipolar, caracterizado porque comprende, como un ingrediente activo, (S)-N-[2-(1,6,7,8-tetrahidro-2H-indeno[5,4-b]furan-8-il)etil]propionamida para la administración por vía oral-mucosa a un ser humano.
ARP120100142A 2011-01-17 2012-01-16 Preparacion de desintegracion rapida, comprimido dispersable por via oral AR084865A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011007371 2011-01-17
JP2011227333 2011-10-14

Publications (1)

Publication Number Publication Date
AR084865A1 true AR084865A1 (es) 2013-07-10

Family

ID=45567081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100142A AR084865A1 (es) 2011-01-17 2012-01-16 Preparacion de desintegracion rapida, comprimido dispersable por via oral

Country Status (24)

Country Link
US (6) US20120282191A1 (es)
EP (1) EP2665465A1 (es)
JP (3) JP5600747B2 (es)
KR (1) KR20140014134A (es)
CN (1) CN103429223A (es)
AR (1) AR084865A1 (es)
AU (1) AU2012207818B2 (es)
BR (1) BR112013017600A2 (es)
CA (1) CA2824430A1 (es)
CL (1) CL2013002033A1 (es)
CO (1) CO6791611A2 (es)
CR (1) CR20130380A (es)
EA (1) EA201391053A1 (es)
EC (1) ECSP13012825A (es)
IL (1) IL227357A0 (es)
MA (1) MA34908B1 (es)
MX (1) MX2013008314A (es)
PE (1) PE20140255A1 (es)
PH (1) PH12013501512A1 (es)
SG (1) SG191964A1 (es)
TW (1) TW201309347A (es)
UY (1) UY33869A (es)
WO (1) WO2012099260A1 (es)
ZA (1) ZA201305567B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
CN103989643B (zh) * 2013-07-26 2018-10-30 武汉先路医药科技有限公司 含有雷美替胺和共聚维酮的片剂
SG11201600455XA (en) * 2013-07-31 2016-02-26 Intelgenx Corp Instantly wettable oral film dosage form without surfactant or polyalcohol
CN105007904A (zh) * 2014-02-07 2015-10-28 科学实验室药物公司 全天然无毒舌下药物递送系统
CN106389361A (zh) * 2016-03-31 2017-02-15 北京万全德众医药生物技术有限公司 一种含有雷美替胺的口腔崩解片及其制备方法
CN105853379A (zh) * 2016-03-31 2016-08-17 北京万全德众医药生物技术有限公司 一种雷美替胺分散片及其制备工艺
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
CN106038502A (zh) * 2016-07-01 2016-10-26 北京万全德众医药生物技术有限公司 一种雷美替胺口崩片及其制备方法
US20210113456A1 (en) * 2017-07-13 2021-04-22 Maxinase Life Sciences Limited Pharmaceutical compositions of ramelteon and methods of use thereof
MX2020011541A (es) 2018-05-02 2020-11-24 Ferring Bv Formulaciones farmaceuticas mejoradas.
JP7552146B2 (ja) * 2019-08-28 2024-09-18 小野薬品工業株式会社 イバブラジンを含有する錠剤
CN113243444A (zh) * 2020-02-13 2021-08-13 罗盖特公司 作为口香糖中的填充剂的多孔淀粉
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物
CN115778925A (zh) * 2022-12-26 2023-03-14 湖北广济医药科技有限公司 一种雷美替胺口溶膜剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
DK0914818T3 (da) 1996-06-14 2005-07-04 Kyowa Hakko Kogyo Kk Intraoralt hurtigt desintegrerbar tablet
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ES2233329T3 (es) 1999-02-15 2005-06-16 Sumitomo Pharmaceuticals Company, Limited Comprimidos que se desintegran rapidamente en la cavidad bucal.
CA2381860C (en) 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
JP4802436B2 (ja) 2000-04-12 2011-10-26 Ｍｓｄ株式会社 口腔内崩壊型組成物及び口腔内崩壊型製剤
US7008642B1 (en) * 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
CN1284532C (zh) * 2001-09-28 2006-11-15 株式会社三和化学研究所 有核型速溶崩解性成型品
FR2834890B1 (fr) 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US20040161459A1 (en) * 2002-12-31 2004-08-19 Ngoc Do Fast-dissolve tablet technology
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
KR20070118103A (ko) * 2005-04-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 우울증 또는 불안신경증의 예방 또는 치료제
US20100011960A1 (en) * 2005-07-18 2010-01-21 Colin Lawrence Electrostatic Air Filter
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
FR2894475B1 (fr) 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
US8486450B2 (en) * 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
US7797869B2 (en) * 2006-07-10 2010-09-21 Tollis David R Multi-section display and utility stanchion
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
BRPI0808889A2 (pt) 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
RU2485949C2 (ru) * 2007-04-11 2013-06-27 Фармасьютикал Продакшнс Инк Таблетка мелатонина и способы изготовления и применения
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2009136240A (ja) 2007-12-10 2009-06-25 Lion Corp チューインガム組成物
US20110130428A1 (en) 2008-06-11 2011-06-02 Astrazeneca Ab Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine
US7833819B2 (en) * 2008-07-23 2010-11-16 Aptina Imaging Corporation Method and apparatus for decreasing storage node parasitic charge in active pixel image sensors
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP2011007371A (ja) 2009-06-23 2011-01-13 Sanyo Electric Co Ltd 空気調和機
JP5513936B2 (ja) * 2010-03-10 2014-06-04 全星薬品工業株式会社 口腔内崩壊製剤
JP5523913B2 (ja) 2010-04-21 2014-06-18 スタンレー電気株式会社 光源装置および照明装置

Also Published As

Publication number Publication date
TW201309347A (zh) 2013-03-01
PH12013501512A1 (en) 2013-09-16
US20170065553A1 (en) 2017-03-09
CL2013002033A1 (es) 2014-01-03
US20130035385A1 (en) 2013-02-07
SG191964A1 (en) 2013-08-30
JP2014198723A (ja) 2014-10-23
AU2012207818B2 (en) 2015-05-14
CR20130380A (es) 2013-10-09
US8642648B2 (en) 2014-02-04
ECSP13012825A (es) 2013-10-31
MX2013008314A (es) 2013-09-26
UY33869A (es) 2012-08-31
US20140235879A1 (en) 2014-08-21
AU2012207818A1 (en) 2013-05-02
KR20140014134A (ko) 2014-02-05
WO2012099260A1 (en) 2012-07-26
ZA201305567B (en) 2014-10-29
BR112013017600A2 (pt) 2016-10-18
US8642649B2 (en) 2014-02-04
IL227357A0 (en) 2013-09-30
PE20140255A1 (es) 2014-03-11
EA201391053A1 (ru) 2013-12-30
JP5600747B2 (ja) 2014-10-01
MA34908B1 (fr) 2014-02-01
NZ613265A (en) 2015-08-28
US20130035384A1 (en) 2013-02-07
JP2013544230A (ja) 2013-12-12
CO6791611A2 (es) 2013-11-14
CA2824430A1 (en) 2012-07-26
EP2665465A1 (en) 2013-11-27
US20140235709A1 (en) 2014-08-21
US20120282191A1 (en) 2012-11-08
CN103429223A (zh) 2013-12-04
JP2016053094A (ja) 2016-04-14

Similar Documents

Publication Publication Date Title
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
NZ727975A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
MX363495B (es) Proceso de manufacturacion de una forma de dosificacion multifasica de rapida disolucion liofilizada.
MX2010001401A (es) Productos medicos mejorados, revestidos con preparaciones farmaceuticas, la produccion de los mismos y el uso de los mismos.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013106172A (ru) Композиция для снятия усталости, состав и их применение
JP2013541583A5 (es)
PE20160183A1 (es) FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056)
EA201391689A1 (ru) Система доставки лекарственного средства
CO6180495A2 (es) Formulacion de medicamento liquida
ES2469240B1 (es) Uso de un agente fotosensible capaz de producir especies reactivas de oxígeno en la preparación de un medicamento útil para la terapia fotodinámica de una enfermedad relacionada con células madre, uso "in vitro" y composición farmacéutica.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
JP2013541582A5 (es)
RU2016144695A (ru) Комплекс танната ситаглиптина
MX2021001845A (es) Un medicamento combinado que comprende fenilefrina y paracetamol.
EA201301275A1 (ru) Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса
DOP2011000267A (es) Composicion farmaceutica oral para uso en enfermedades respiratorias
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
EA201991359A1 (ru) Фармацевтические лекарственные формы
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
MX2011011879A (es) Uso de las betaxantinas y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes.

Legal Events

Date Code Title Description
FB Suspension of granting procedure